Zhejiang Jolly Valuation Multiples

Zhejiang Jolly Overview

About Zhejiang Jolly

Zhejiang Jolly Pharmaceutical Co Ltd is a China-based company engaged in the production and distribution of pharmaceutical products. Its production lines include raw materials, tablets, capsules, particles and frozen dry powder injection. Its products include Wuling powder, Wuling capsule, linglianhua particle, clindamycin phosphate injection and other.

Founded

2000

HQ

Employees

N/A

Website

zuoli.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $468M

EBITDA: $137M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Zhejiang Jolly Financials

Zhejiang Jolly reported last 12-month revenue of $468M and EBITDA of $137M.

In the same LTM period, Zhejiang Jolly generated $293M in gross profit, $137M in EBITDA, and $105M in net income.

Zhejiang Jolly P&L

In the most recent fiscal year, Zhejiang Jolly reported revenue of $378M and EBITDA of $99M.

Zhejiang Jolly expects next 12-month revenue of XXX and NTM EBITDA of XXX

Zhejiang Jolly Stock Performance

Zhejiang Jolly has current market cap of $2B, and enterprise value of $2B.

Zhejiang Jolly's stock price is $2.28.

Zhejiang Jolly Valuation Multiples

Zhejiang Jolly trades at 3.4x EV/Revenue multiple, and 11.6x EV/EBITDA.

Zhejiang Jolly Financial Valuation Multiples

As of April 18, 2026, Zhejiang Jolly has market cap of $2B and EV of $2B.

Equity research analysts estimate Zhejiang Jolly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zhejiang Jolly has a P/E ratio of 15.2x.

Zhejiang Jolly Margins & Growth Rates

Zhejiang Jolly's revenue in the last 12 month grew by 22%.

Zhejiang Jolly's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhejiang Jolly's rule of X is 90% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Zhejiang Jolly Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Zhejiang Jolly M&A Activity

Zhejiang Jolly acquired XXX companies to date.

Last acquisition by Zhejiang Jolly was on XXXXXXXX, XXXXX. Zhejiang Jolly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Zhejiang Jolly Investment Activity

Zhejiang Jolly invested in XXX companies to date.

Zhejiang Jolly made its latest investment on XXXXXXXX, XXXXX. Zhejiang Jolly invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).